Anika Therapeutics, INC 10-Q quarterly reports

Anika Therapeutics reports significant revenue growth and improved gross margins in Q2 2026, driven by strong performance in its OEM and Commercial Channels.

Anika Therapeutics reported a net loss of $2.3 million in Q3 2025, with revenue declining 6% year-over-year, primarily due to lower OEM channel pricing, despite growth in its Commercial Channel.

Anika Therapeutics reported a significant net loss and revenue decline in the second quarter of 2025, compounded by its Hyalofast cartilage repair therapy failing to meet co-primary endpoints in a pivotal U.S. Phase III trial.

Anika Therapeutics' Q1 2025 results reveal a revenue decrease of 10% due to lower OEM sales and discontinued operations, as the company focuses on OA Pain Management and Regenerative Solutions businesses.

Anika Therapeutics reported a net loss for Q3 2024 and announced the sale of its Arthrosurface business and plans to divest Parcus Medical to focus on core HA technology.

Anika Therapeutics experienced a slight revenue decrease in Q2 2024, alongside a reduction in net loss compared to the same period last year, as the company navigates strategic changes and market dynamics.

Anika Therapeutics saw a revenue increase and a reduction in net losses in the first quarter of 2024 compared to the same period last year.